Related Experiment Video
Updated: Jun 27, 2026
08:41
Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
Published on: March 24, 2023
The Pathophysiological Interrelationship Between Metabolic Dysfunction-Associated Steatotic Liver Disease and
Adrián Róbert Gál1,2, István Szokodi1,3,4, Zoltán Vizvári2,5,6
1Institute of Physiology, Medical School, University of Pécs, 7624 Pécs, Hungary.
Antioxidants (Basel, Switzerland)
|June 26, 2026
Summary
Metabolic dysfunction-associated steatotic liver disease (MASLD) significantly elevates cardiovascular disease risk, driven by metabolic dysfunction and oxidative stress. Early detection and integrated therapies targeting shared pathways are crucial for managing this risk.
Area of Science:
- Cardiology
- Hepatology
- Metabolic Disorders
Background:
- Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent condition linked to increased cardiovascular disease (CVD) mortality.
- MASLD stems from hepatic lipid accumulation, lipotoxicity, and mitochondrial dysfunction, exacerbated by oxidative stress.
- Systemic metabolic dysregulation in MASLD contributes to atherogenic dyslipidemia, inflammation, and gut dysbiosis.
Purpose of the Study:
- To elucidate the integrated pathophysiology linking MASLD to cardiovascular complications.
- To highlight emerging biomarkers and screening strategies for subclinical cardiovascular involvement in MASLD patients.
- To discuss pharmacological approaches targeting shared metabolic pathways.
Main Methods:
- Review of current literature on MASLD pathophysiology and cardiovascular manifestations.
- Analysis of the role of oxidative stress, inflammation, and gut dysbiosis in disease progression.
- Exploration of biomarkers and therapeutic strategies.
Main Results:
- MASLD promotes cardiovascular risk through lipid dysregulation, oxidative stress, and inflammation.
- Reactive oxygen species (ROS) and glutathione depletion link MASLD to vascular and myocardial dysfunction.
- MASLD is associated with increased coronary artery disease and heart failure, especially heart failure with preserved ejection fraction.
Conclusions:
- MASLD acts as a significant cardiovascular risk amplifier.
- Early identification of cardiovascular involvement and multidisciplinary screening are essential.
- Integrated therapeutic strategies targeting shared metabolic pathways are needed for effective risk management.
Related Concept Videos
01:24Overview of Lipid Metabolism
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
01:24Cirrhosis II: Pathophysiology
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:26Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
01:30Coronary Artery Disease I: Introduction
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...